Press Releases
Mayo Clinic Teams with Glowing Cats Against AIDS, Other Diseases
Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The...
Press Releases
Exelixis Announces Webcasts of Upcoming Investor Conference Presentations Exelixis Inc.
Exelixis, Inc. announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences. Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20...
Press Releases
Sucampo and Numab Sign Drug Discovery Collaboration Sucampo Pharmaceuticals Inc. and Numab AG
Sucampo Pharmaceuticals, Inc. an international pharmaceutical company, and Numab AG today announced that Sucampo’s wholly owned subsidiary, Sucampo AG, and Numab AG, have entered into a research and development collaboration that provides Sucampo with access to Numab’s proprietary...
Press Releases
Over 65% of Physicians Have Used Social Media to Support their Professional Practice
Physicians are highly engaged with social media for both personal and professional use, according to a 4,033-clinician study authored and conducted by QuantiaMD, the largest mobile and online physician community, and Care Continuum Alliance, an international association for...
Press Releases
Trophos completes patient enrolment in pivotal efficacy study of olesoxime in Spinal Muscular Atrophy
Marseille France, September 8, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment in the...
Press Releases
BARDA Partners to Develop New Class of Antibiotic U.S. Department of Health and Human Services
The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening...
Press Releases
Synta to Present at the Rodman & Renshaw Annual Global Investment Conference Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13 at 11:15 a.m. (ET) in New York. About Synta...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read